← Leaderboards
Xifeng Wu
University Of Texas Md Anderson Can Ctr
$28,679,533
Attributed
$31,916,875
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$31,916,875 · 19
By mechanism
R01$18,041,126 · 8
P50$7,834,047 · 8
U01$5,108,770 · 1
P01$922,932 · 1
R13$10,000 · 1
Top collaborators
- Ashish M Kamat5 shared
- Seth P. Lerner5 shared
- Jian Gu4 shared
- Lidong Qin4 shared
- Jack Roth4 shared
- Lin Ji3 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Scott M Lippman$54,535,308
- Margaret R Spitz$17,223,484
- Robert A. Newman$3,418,666
- Reuben Lotan$1,675,909
- Jack Roth$8,028,008
Others in their field
Top investigators on “Genotype”
- David R. Weir · University Of Michigan At Ann Arbor$303,033,420
- Richard A Gibbs · Baylor College Of Medicine$211,329,145
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Stacey Gabriel · Massachusetts Institute Of Technology$153,486,482
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$141,132,078
Research focus
GenotypeGeneticBaseGenesPredispositionEpidemiologyMolecularPathway InteractionsCancer RiskMalignant NeoplasmsFrequencies (Time Pattern)High RiskPhenotypeStagingDesignSingle Nucleotide PolymorphismSubgroupGenetic PolymorphismFollow-UpBiologicalVariation (Genetics)LymphocyteTumorSpecimen
Grant awards (80)
Mitochondria, MicroRNA, and Metabolites in Predicting Aggressive Prostate Cancer$268,604
P50 · FY2019 · CA · contact PI
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$479,955
R01 · FY2017 · CA · contact PI
Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways: Risk of Lung Cancer Development and Recurrence$447,453
P50 · FY2017 · CA · contact PI
Mitochondria, MicroRNA, and Metabolites in Predicting Aggressive Prostate Cancer$244,139
P50 · FY2017 · CA · contact PI
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip$505,194
R01 · FY2016 · CA
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$494,829
R01 · FY2016 · CA · contact PI
Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways: Risk of Lung Cancer Development and Recurrence$420,606
P50 · FY2016 · CA · contact PI
Mitochondria, MicroRNA, and Metabolites in Predicting Aggressive Prostate Cancer$293,268
P50 · FY2016 · CA · contact PI
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$217,966
P50 · FY2016 · CA · contact PI
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip$521,783
R01 · FY2015 · CA
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$519,312
R01 · FY2015 · CA · contact PI
Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways: Risk of Lung Cancer Development and Recurrence$397,497
P50 · FY2015 · CA · contact PI
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$228,909
P50 · FY2015 · CA · contact PI
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)$521,201
R01 · FY2014 · CA · contact PI
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$519,312
R01 · FY2014 · CA · contact PI
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip$506,129
R01 · FY2014 · CA
Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways: Risk of Lung Cancer Development and Recurrence$424,704
P50 · FY2014 · CA · contact PI
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$225,831
P50 · FY2014 · CA · contact PI
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip$534,498
R01 · FY2013 · CA
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)$505,315
R01 · FY2013 · CA · contact PI
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$224,314
P50 · FY2013 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$105,695
P50 · FY2013 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$769,079
U01 · FY2012 · CA · contact PI
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)$545,964
R01 · FY2012 · CA · contact PI
Genetic Instability & Risk for Esophageal Carcinoma$503,936
R01 · FY2012 · CA · contact PI
Cancer Risk Assessment in Patients with Oral Premalignant Lesions$380,548
P50 · FY2012 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$355,330
P50 · FY2012 · CA · contact PI
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$203,201
P50 · FY2012 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$669,490
U01 · FY2011 · CA · contact PI
Genetic Instability & Risk for Esophageal Carcinoma$579,514
R01 · FY2011 · CA · contact PI
Cancer Risk Assessment in Patients with Oral Premalignant Lesions$356,374
P50 · FY2011 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$337,753
P50 · FY2011 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$1,196,434
U01 · FY2010 · CA · contact PI
Genetic Instability & Risk for Esophageal Carcinoma$598,914
R01 · FY2010 · CA · contact PI
Cancer Risk Assessment in Patients with Oral Premalignant Lesions$392,398
P50 · FY2010 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$355,249
P50 · FY2010 · CA · contact PI
Markers of Susceptibility as Predictors of Blasser Cancer Recurrence$286,458
P50 · FY2010 · CA · contact PI
4th Meeting of the International Consortium of Bladder Cancer (ICBC)$10,000
R13 · FY2010 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$1,090,595
U01 · FY2009 · CA · contact PI
Genetic Instability & Risk for Esophageal Carcinoma$588,600
R01 · FY2009 · CA · contact PI
Lung Cancer Chemoradiation: Predictors of Survival$538,470
R01 · FY2009 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$354,719
P50 · FY2009 · CA · contact PI
Cancer Risk Assessment in Patients with Oral Premalignant Lesions$354,491
P50 · FY2009 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$305,756
U01 · FY2009 · CA · contact PI
Markers of Susceptibility as Predictors of Blasser Cancer Recurrence$262,931
P50 · FY2009 · CA · contact PI
Lung Cancer Chemoradiation: Predictors of Survival$243,158
R01 · FY2009 · CA · contact PI
Genome-Wide Association Analysis of Bladder Cancer$1,077,416
U01 · FY2008 · CA · contact PI
Genetic Instability & Risk for Esophageal Carcinoma$589,746
R01 · FY2008 · CA · contact PI
Lung Cancer Chemoradiation: Predictors of Survival$523,158
R01 · FY2008 · CA · contact PI
Markers of Genetic Susceptibility to Bladder Cancer$310,785
R01 · FY2008 · CA · contact PI
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome$283,345
P50 · FY2008 · CA · contact PI
P2: Cancer Risk Assessment in Patients with Oral Premalignant Lesions$220,258
P50 · FY2008 · CA · contact PI
Markers of Susceptibility as Predictors of Blasser Cancer Recurrence$192,006
P50 · FY2008 · CA · contact PI
MOLECULAR EPIDEMIOLOGY /PHARMACOGENOMICS IN ORAL CANCER$112,542
P01 · FY2008 · CA · contact PI
Lung Cancer Chemoradiation: Predictors of Survival$518,356
R01 · FY2007 · CA · contact PI
Genetic Susceptibility Modifiers in Renal Cell Carcinoma$460,591
R01 · FY2007 · CA · contact PI
Markers of Genetic Susceptibility to Bladder Cancer$358,921
R01 · FY2007 · CA · contact PI
MOLECULAR EPIDEMIOLOGY /PHARMACOGENOMICS IN ORAL CANCER$257,143
P01 · FY2007 · CA · contact PI
Genetic Susceptibility Modifiers in Renal Cell Carcinoma$535,982
R01 · FY2006 · CA · contact PI
Lung Cancer Chemoradiation: Predictors of Survival$518,680
R01 · FY2006 · CA · contact PI
Markers of Genetic Susceptibility to Bladder Cancer$360,902
R01 · FY2006 · CA · contact PI
MOLECULAR EPIDEMIOLOGY /PHARMACOGENOMICS IN ORAL CANCER$187,782
P01 · FY2006 · CA · contact PI
Genetic Susceptibility Modifiers in Renal Cell Carcinoma$526,156
R01 · FY2005 · CA
Lung Cancer Chemoradiation: Predictors of Survival$521,682
R01 · FY2005 · CA
Markers of Genetic Susceptibility to Bladder Cancer$357,683
R01 · FY2005 · CA
MOLECULAR EPIDEMIOLOGY /PHARMACOGENOMICS IN ORAL CANCER$182,312
P01 · FY2005 · CA
Genetic Susceptibility Modifiers in Renal Cell Carcinoma$511,396
R01 · FY2004 · CA
Markers of Genetic Susceptibility to Bladder Cancer$365,367
R01 · FY2004 · CA
GENETIC INFLUENCE ON MUTAGEN SENSITIVITY--A TWIN STUDY$271,410
R01 · FY2004 · CA
MOLECULAR EPIDEMIOLOGY /PHARMACOGENOMICS IN ORAL CANCER$183,153
P01 · FY2004 · CA
Genetic Susceptibility Modifiers in Renal Cell Carcinoma$478,404
R01 · FY2003 · CA
GENETIC INFLUENCE ON MUTAGEN SENSITIVITY--A TWIN STUDY$272,240
R01 · FY2003 · CA
GENETIC SUSCEPTIBILITY TO BLADDER CANCER$268,904
R01 · FY2003 · CA
GENETIC SUSCEPTIBILITY TO BLADDER CANCER$357,088
R01 · FY2002 · CA
GENETIC INFLUENCE ON MUTAGEN SENSITIVITY--A TWIN STUDY$261,035
R01 · FY2002 · CA
MARKERS OF SUSCEPTIBILITY AS PREDICTOR OF BLADDER CANCER$0
P50 · FY2002 · CA
GENETIC SUSCEPTIBILITY TO BLADDER CANCER$346,806
R01 · FY2001 · CA
GENETIC INFLUENCE ON MUTAGEN SENSITIVITY--A TWIN STUDY$282,923
R01 · FY2001 · CA
MARKERS OF SUSCEPTIBILITY AS PREDICTOR OF BLADDER CANCER$0
P50 · FY2001 · CA
GENETIC SUSCEPTIBILITY TO BLADDER CANCER$336,827
R01 · FY2000 · CA